Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
16,724,051
-
Total 13F shares
-
624,408
-
Share change
-
-464,256
-
Total reported value
-
$773,221
-
Put/Call ratio
-
9.5%
-
Price per share
-
$1.24
-
Number of holders
-
34
-
Value change
-
-$686,704
-
Number of buys
-
17
-
Number of sells
-
10
Institutional Holders of Citius Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (CTXR) as of Q3 2025
As of 30 Sep 2025,
Citius Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (CTXR) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
624,408 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, NORTHERN TRUST CORP, UBS Group AG, NewEdge Advisors, LLC, STATE STREET CORP, TWO SIGMA INVESTMENTS, LP, and Arkadios Wealth Advisors.
This page lists
34
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.